[go: up one dir, main page]

CL2004000496A1 - Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente - Google Patents

Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente

Info

Publication number
CL2004000496A1
CL2004000496A1 CL200400496A CL2004000496A CL2004000496A1 CL 2004000496 A1 CL2004000496 A1 CL 2004000496A1 CL 200400496 A CL200400496 A CL 200400496A CL 2004000496 A CL2004000496 A CL 2004000496A CL 2004000496 A1 CL2004000496 A1 CL 2004000496A1
Authority
CL
Chile
Prior art keywords
fluoroanilino
phenylacetic
chlorine
oral administration
treat
Prior art date
Application number
CL200400496A
Other languages
English (en)
Inventor
Patrick Khaled Maha Y Forenzo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2004000496A1 publication Critical patent/CL2004000496A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PROPORCIONAN COMPOSICIONES QUE COMPRENDEN SUSPENSIONES ACUOSAS DE ACIDO 5-METIL-2-(22--CLORO-62--FLUOROANILINO)FENILACETICO ADECUADAS PARA ADMINISTRACION ORAL. TAMBIEN SE PROPORCIONAN METODOS PARA HACER DICHAS COMPOSICIONES Y METODOS PARA SU ESTABILIZACION.
CL200400496A 2003-03-12 2004-03-11 Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente CL2004000496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12

Publications (1)

Publication Number Publication Date
CL2004000496A1 true CL2004000496A1 (es) 2005-01-14

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400496A CL2004000496A1 (es) 2003-03-12 2004-03-11 Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente

Country Status (29)

Country Link
US (2) US20060094787A1 (es)
EP (1) EP1603550B1 (es)
JP (1) JP4580921B2 (es)
KR (1) KR20050109077A (es)
CN (1) CN100345536C (es)
AR (1) AR043536A1 (es)
AT (1) ATE418332T1 (es)
AU (1) AU2004218921B2 (es)
BR (1) BRPI0408270A (es)
CA (1) CA2518393A1 (es)
CL (1) CL2004000496A1 (es)
DE (1) DE602004018622D1 (es)
EC (1) ECSP055998A (es)
ES (1) ES2318277T3 (es)
HR (1) HRP20050787A2 (es)
IL (1) IL170518A (es)
IS (1) IS2658B (es)
MA (1) MA27670A1 (es)
MX (1) MXPA05009686A (es)
MY (1) MY139455A (es)
NO (1) NO20054662L (es)
NZ (1) NZ542218A (es)
PE (1) PE20041063A1 (es)
PT (1) PT1603550E (es)
RU (1) RU2363462C2 (es)
TN (1) TNSN05222A1 (es)
TW (1) TWI327913B (es)
WO (1) WO2004080451A1 (es)
ZA (1) ZA200506750B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070123593A1 (en) * 2003-10-08 2007-05-31 Rose-Marie Dannenfelser Pharmaceutical composition comprising 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
RU2488393C2 (ru) * 2007-11-12 2013-07-27 Новартис Аг Жидкие композиции, включающие валсартан
EP2926810A1 (en) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of loxoprofen
US11207307B2 (en) 2016-06-16 2021-12-28 Azurity Pharmaceuticals, Inc. Composition and method for proton pump inhibitor suspension
CA3036356A1 (en) 2016-09-09 2018-03-15 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES
US10751333B1 (en) * 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
CA2472585A1 (en) * 2002-01-07 2003-07-17 Pharmacia Corporation Drug mixture with enhanced dissolution rate
WO2003086282A2 (en) * 2002-04-05 2003-10-23 Nitromed, Inc. Nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
KR20050109077A (ko) 2005-11-17
EP1603550B1 (en) 2008-12-24
RU2005131310A (ru) 2006-05-10
MXPA05009686A (es) 2005-10-20
WO2004080451A1 (en) 2004-09-23
BRPI0408270A (pt) 2006-03-07
ATE418332T1 (de) 2009-01-15
IL170518A (en) 2010-11-30
IS8049A (is) 2005-09-28
IS2658B (is) 2010-08-15
JP4580921B2 (ja) 2010-11-17
DE602004018622D1 (de) 2009-02-05
ECSP055998A (es) 2006-01-27
EP1603550A1 (en) 2005-12-14
AU2004218921A1 (en) 2004-09-23
TW200505429A (en) 2005-02-16
MY139455A (en) 2009-10-30
AR043536A1 (es) 2005-08-03
NO20054662L (no) 2005-12-05
RU2363462C2 (ru) 2009-08-10
AU2004218921B2 (en) 2007-05-17
CA2518393A1 (en) 2004-09-23
MA27670A1 (fr) 2005-12-01
CN100345536C (zh) 2007-10-31
CN1756541A (zh) 2006-04-05
JP2006519811A (ja) 2006-08-31
HRP20050787A2 (en) 2006-12-31
US20090048344A1 (en) 2009-02-19
TNSN05222A1 (en) 2007-06-11
ZA200506750B (en) 2007-02-28
US20060094787A1 (en) 2006-05-04
TWI327913B (en) 2010-08-01
HK1086492A1 (en) 2006-09-22
NO20054662D0 (no) 2005-10-11
PT1603550E (pt) 2009-03-20
NZ542218A (en) 2009-01-31
ES2318277T3 (es) 2009-05-01
PE20041063A1 (es) 2005-03-07

Similar Documents

Publication Publication Date Title
ECSP044974A (es) Formulación de suspensión oral estabilizada
ATE429210T1 (de) Orale flüssige zusammensetzungen
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
DK1311256T3 (da) Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
BR9916076A (pt) Composição adequada para aplicação tópica, uso de uma composição tópica métodos para melhorar o distúrbio do estìmulo sexual feminino, e para intensificar o estìmulo sexual feminino, e a resposta sexual feminina, artigo de manufatura
TW200510375A (en) New compounds
EE05382B1 (et) MandelhappeÁderivaadid,ÁnendeÁvalmistamiseÁmeetod,ÁnendeÁkasutamineÁtrombiiniÁinhibiitoritenaÁjaÁneidÁsisaldavadÁravimkoostised
MXPA05008409A (es) Formulacion de inmunoglobulina y metodo para la preparacion de la misma.
BR0115354A (pt) Composições de suspensão de lìquidos estáveis, método de preparo e uso das mesmas
CL2004000496A1 (es) Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
EE200200252A (et) Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks
ATE352287T1 (de) Flüssige pharmazeutische zusammensetzungen auf wasserbasis in suspensionsform zur oralen verabreichung von ibuprofen
ATE131031T1 (de) Zubereitung zur topischen anwendung.
ITTO20010028A0 (it) Metodo per aumentare l'attivita' antitumorale di una sostanza contenente amigdalina, composizione contenente una sostanza con contenuto aume
BR9908838A (pt) Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
SE9902742D0 (sv) New pharmaceutical formultion
UY27376A1 (es) Formulación de medicamento que contiene un antagonista de ltb4
TH77904A (th) สารผสมทางเภสัชกรรม